Study S002377

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone

ClinicalTrials.gov record

Registration

Registration: NCT00744367
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 326
Start: 2008-10
Primary completion: 2010-11
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:metformin; DRUG:pioglitazone; DRUG:placebo; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2008-001744-39; NIH:2008

Registered primary outcomes

Absolute change from baseline in HbA1c [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.